Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Tadalafil 2.5Mg Tab
Hospital Authority, Hong Kong
Erectile Dysfunction
1 trial -
Tafolecimab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Coronary Syndrome
1 trial -
Targeted Amino Acid Supplement
United Therapeutics Europe Ltd
Parkinson Disease (PD)
1 trial -
Tegoprazan-amoxicillin dual therapy
The First People's Hospital of Lianyungang
Helicobacter Pylori Infection
1 trial -
Tenofovir Disoproxil Fumarate
The First People's Hospital of Lianyungang
Hepatitis B, Chronic
1 trial -
Terlipressin
The First People's Hospital of Lianyungang
Terlipressin
1 trial -
Test Formula
United Therapeutics Europe Ltd
Cow's Milk Allergy
1 trial -
Tests of the expression of CXCL3 in various tissues
The First People's Hospital of Lianyungang
Diabetic Kidney Disease (DKD)
1 trial -
Thalidomide
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma
1 trial -
The specific drug comes from "GINA (2024)"
The First People's Hospital of Lianyungang
Asthma
1 trial -
Thoracic Paravertebral Block with Local Anesthetic
The First People's Hospital of Lianyungang
Pulmonary Nodules
1 trial -
Tianqi Pingchan Granule
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Levodopa-Induced Dyskinesia
1 trial -
Ticagrelor monotherapy
The First People's Hospital of Lianyungang
Intracranial Aneurysm
1 trial -
Tislelizumab combined with Lenvatinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Initially Unresectable Hepatocellular Carcinoma
1 trial -
To withdraw NSAIDs therapy
The First People's Hospital of Lianyungang
Axial Spondyloarthritis
1 trial -
Total glucosides of paeony & Acitretin Capsules
The First People's Hospital of Lianyungang
Psoriasis
1 trial -
UE
The First People's Hospital of Lianyungang
Lung Cancer
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Multiple Sclerosis (MS) - Relapsing-remitting
1 trial -
Ulinastatin
The First People's Hospital of Lianyungang
Acute Respiratory Distress Syndrome
1 trial -
Urinary kallidinogenase for injection
The First People's Hospital of Lianyungang
Acute Ischemic Stroke
1 trial -
Use baby moisturizers by NeoChine
The First People's Hospital of Lianyungang
Neonatal Jaundice
1 trial -
Use of Mitomycin-C in trabeculectomy
AEON Biopharma
Open-angle Glaucoma
1 trial -
Using medical biological glue for filling And Using the meniscus suture system
The First People's Hospital of Lianyungang
Unilateral Meniscus Tear of the Knee Joint
1 trial -
Valerian
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Menopausal Women
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources